Monopar Presents New Phase 3 Analyses Showing Greater Neurologic & Global Benefit for ALXN1840 in Wilson Disease
MNPR has more than doubled off its 52-week low of $29.18.
Summary
Monopar Therapeutics announced new analyses from its Phase 3 trial for ALXN1840, showing greater neurologic and global clinical benefits in Wilson disease patients, further supporting its upcoming FDA submission.
Key Events · Product Development and Regulatory · MNPR
-
New Phase 3 Data Analyses
Monopar presented new analyses from its Phase 3 FoCus trial for ALXN1840 in Wilson disease.
-
Superior Clinical Benefit
The analyses demonstrated greater neurologic and global clinical benefit compared to standard of care in patients with neurologic symptoms.
-
Conference Presentation
These findings will be presented at the 12th Congress of the European Academy of Neurology (EAN) from June 27-30, 2026.
-
NDA Submission Support
The positive results further support the planned New Drug Application (NDA) submission to the FDA for ALXN1840 in mid-2026.
Analysis · MNPR · Life Sciences
This 8-K announces new, detailed analyses from the Phase 3 FoCus trial for ALXN1840 in Wilson disease, demonstrating superior neurologic and global clinical benefits compared to standard of care. These findings, to be presented at a major neurology conference, significantly strengthen the drug's profile and reinforce the company's planned mid-2026 NDA submission to the FDA.
At the time of this filing, MNPR was trading at $87.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $587.4M. The 52-week trading range was $29.18 to $105.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.